1 97th United States Congress. Public law 97-414 an act to amend the Federal Food, Drug, and Cosmetic Act to facilitate the development of drugs for rare diseases and conditions, and for other purposes[Z]. Washington: Senate and House of Representatives of the United States of America in Congress assembled, 1983.
2 尹薇. 中国罕见病定义研究报告发布: 患病人数小于14万为罕见病[EB/OL]. (2021-09-12)[2023-03-15]. https://baijiahao.baidu.com/s?id=1710682019865110353&wfr=spider&for=pc.
3 Rubin R. New funding for research into rare diseases treatments[J]. JAMA, 2022, 328(19): 1898-1899. PMID: 36378219. DOI: 10.1001/jama.2022.18479.
4 陈晨, 韩晓红. 中国罕见病药物临床试验10年现状分析:基于《第一批罕见病目录》[J]. 协和医学杂志, 2022, 13(6): 1028-1035. DOI: 10.12290/xhyxzz.2022-0010.
5 Lachmann RH. Treating lysosomal storage disorders: what have we learnt?[J]. J Inherit Metab Dis, 2020, 43(1): 125-132. PMID: 31140601. DOI: 10.1002/jimd.12131.
6 Kleppin S. Enzyme replacement therapy for lysosomal storage diseases[J]. J Infus Nurs, 2020, 43(5): 243-245. PMID: 32881810. DOI: 10.1097/NAN.0000000000000390.
7 Parini R, Deodato F. Intravenous enzyme replacement therapy in mucopolysaccharidoses: clinical effectiveness and limitations[J]. Int J Mol Sci, 2020, 21(8): 2975. PMID: 32340185. PMCID: PMC7215308. DOI: 10.3390/ijms21082975.
8 Jameson E, Jones S, Remmington T. Enzyme replacement therapy with laronidase (Aldurazyme?) for treating mucopolysaccharidosis type I[J]. Cochrane Database Syst Rev, 2019, 6(6): CD009354. PMID: 31211405. PMCID: PMC6581069. DOI: 10.1002/14651858.CD009354.pub5.
9 Muenzer J, Vijayaraghavan S, Stein M, et al. Long-term open-label phase I/II extension study of intrathecal idursulfase-IT in the treatment of neuronopathic mucopolysaccharidosis II[J]. Genet Med, 2022, 24(7): 1437-1448. PMID: 35588317. DOI: 10.1016/j.gim.2022.04.002.
10 Wijburg FA, Heap F, Rust S, et al. Long-term safety and clinical outcomes of intrathecal heparan-N-sulfatase in patients with Sanfilippo syndrome type A[J]. Mol Genet Metab, 2021, 134(4): 317-322. PMID: 34600820. DOI: 10.1016/j.ymgme.2021.09.003.
11 Lee CL, Chuang CK, Chiu HC, et al. Clinical utility of elosulfase alfa in the treatment of Morquio A syndrome[J]. Drug Des Devel Ther, 2022, 16: 143-154. PMID: 35046639. PMCID: PMC8759989. DOI: 10.2147/DDDT.S219433.
12 Dubot P, Sabourdy F, Plat G, et al. First report of a patient with MPS type VII, due to novel mutations in GUSB, who underwent enzyme replacement and then hematopoietic stem cell transplantation[J]. Int J Mol Sci, 2019, 20(21): 5345. PMID: 31661765. PMCID: PMC6861985. DOI: 10.3390/ijms20215345.
13 Nakamura K, Kawashima S, Tozawa H, et al. Pharmacokinetics and pharmacodynamics of JR-051, a biosimilar of agalsidase beta, in healthy adults and patients with Fabry disease: phase I and II/III clinical studies[J]. Mol Genet Metab, 2020, 130(3): 215-224. PMID: 32389574. DOI: 10.1016/j.ymgme.2020.04.003.
14 Diaz GA, Jones SA, Scarpa M, et al. One-year results of a clinical trial of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency[J]. Genet Med, 2021, 23(8): 1543-1550. PMID: 33875845. PMCID: PMC8354848. DOI: 10.1038/s41436-021-01156-3.
15 Sagara R, Ishigaki M, Otsuka M, et al. Long-term safety and effectiveness of velaglucerase alfa in Gaucher disease: 6-year interim analysis of a post-marketing surveillance in Japan[J]. Orphanet J Rare Dis, 2021, 16(1): 502. PMID: 34863216. PMCID: PMC8642863. DOI: 10.1186/s13023-021-02119-2.
16 Okuyama T, Eto Y, Sakai N, et al. A phase 2/3 trial of pabinafusp alfa, IDS fused with anti-human transferrin receptor antibody, targeting neurodegeneration in MPS-II[J]. Mol Ther, 2021, 29(2): 671-679. PMID: 33038326. PMCID: PMC7854283. DOI: 10.1016/j.ymthe.2020.09.039.
17 Diaz-Manera J, Kishnani PS, Kushlaf H, et al. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial[J]. Lancet Neurol, 2021, 20(12): 1012-1026. PMID: 34800399. DOI: 10.1016/S1474-4422(21)00241-6.
18 Schmidt D, Thompson C. Case studies in rare disease small molecule discovery and development[J]. Bioorg Med Chem Lett, 2020, 30(21): 127462. PMID: 32791196. DOI: 10.1016/j.bmcl.2020.127462.
19 Tambuyzer E, Vandendriessche B, Austin CP, et al. Therapies for rare diseases: therapeutic modalities, progress and challenges ahead[J]. Nat Rev Drug Discov, 2020, 19(2): 93-111. PMID: 31836861. DOI: 10.1038/s41573-019-0049-9.
20 Scotet V, Gutierrez H, Farrell PM. Newborn screening for CF across the globe—where is it worthwhile?[J]. Int J Neonatal Screen, 2020, 6(1): 18. PMID: 33073015. PMCID: PMC7422974. DOI: 10.3390/ijns6010018.
21 Mall MA, Mayer-Hamblett N, Rowe SM. Cystic fibrosis: emergence of highly effective targeted therapeutics and potential clinical implications[J]. Am J Respir Crit Care Med, 2020, 201(10): 1193-1208. PMID: 31860331. PMCID: PMC7233349. DOI: 10.1164/rccm.201910-1943SO.
22 Bobadilla JL, Macek M, Fine JP, et al. Cystic fibrosis: a worldwide analysis of CFTR mutations—correlation with incidence data and application to screening[J]. Hum Mutat, 2002, 19(6): 575-606. PMID: 12007216. DOI: 10.1002/humu.10041.
23 Yu H, Burton B, Huang CJ, et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations[J]. J Cyst Fibros, 2012, 11(3): 237-245. PMID: 22293084. DOI: 10.1016/j.jcf.2011.12.005.
24 Liu J, Berg AP, Wang Y, et al. A small molecule CFTR potentiator restores ATP-dependent channel gating to the cystic fibrosis mutant G551D-CFTR[J]. Br J Pharmacol, 2022, 179(7): 1319-1337. PMID: 34644413. PMCID: PMC9304199. DOI: 10.1111/bph.15709.
25 Wang J, Yu Q, Ma X, et al. Hutchinson-Gilford progeria syndrome complicated with stroke: a report of 2 cases and literature review[J]. Front Pediatr, 2022, 10: 1056225. PMID: 36523395. PMCID: PMC9745312. DOI: 10.3389/fped.2022.1056225.
26 Koblan LW, Erdos MR, Wilson C, et al. In vivo base editing rescues Hutchinson-Gilford progeria syndrome in mice[J]. Nature, 2021, 589(7843): 608-614. PMID: 33408413. PMCID: PMC7872200. DOI: 10.1038/s41586-020-03086-7.
27 Chang W, Wang Y, Luxton GWG, et al. Imbalanced nucleocytoskeletal connections create common polarity defects in progeria and physiological aging[J]. Proc Natl Acad Sci U S A, 2019, 116(9): 3578-3583. PMID: 30808750. PMCID: PMC6397528. DOI: 10.1073/pnas.1809683116.
28 Macicior J, Marcos-Ramiro B, Ortega-Gutiérrez S. Small-molecule therapeutic perspectives for the treatment of progeria[J]. Int J Mol Sci, 2021, 22(13): 7190. PMID: 34281245. PMCID: PMC8267806. DOI: 10.3390/ijms22137190.
29 Dhillon S. Lonafarnib: first approval[J]. Drugs, 2021, 81(2): 283-289. PMID: 33590450. PMCID: PMC7985116. DOI: 10.1007/s40265-020-01464-z.
30 Marcos-Ramiro B, Gil-Ordó?ez A, Marín-Ramos NI, et al. Isoprenylcysteine carboxylmethyltransferase-based therapy for Hutchinson-Gilford progeria syndrome[J]. ACS Cent Sci, 2021, 7(8): 1300-1310. PMID: 34471675. PMCID: PMC8393201. DOI: 10.1021/acscentsci.0c01698.
31 Lee SJ, Jung YS, Yoon MH, et al. Interruption of progerin-lamin A/C binding ameliorates Hutchinson-Gilford progeria syndrome phenotype[J]. J Clin Invest, 2016, 126(10): 3879-3893. PMID: 27617860. PMCID: PMC5096810. DOI: 10.1172/JCI84164.
32 Larrieu D, Britton S, Demir M, et al. Chemical inhibition of NAT10 corrects defects of laminopathic cells[J]. Science, 2014, 344(6183): 527-532. PMID: 24786082. PMCID: PMC4246063. DOI: 10.1126/science.1252651.
33 Balmus G, Larrieu D, Barros AC, et al. Targeting of NAT10 enhances healthspan in a mouse model of human accelerated aging syndrome[J]. Nat Commun, 2018, 9(1): 1700. PMID: 29703891. PMCID: PMC5923383. DOI: 10.1038/s41467-018-03770-3.
34 Zeng R, Glaubitz S, Schmidt J. Antibody therapies in autoimmune inflammatory myopathies: promising treatment options[J]. Neurotherapeutics, 2022, 19(3): 911-921. PMID: 35394612. PMCID: PMC9294121. DOI: 10.1007/s13311-022-01220-z.
35 Ossart J, Moreau A, Autrusseau E, et al. Breakdown of immune tolerance in AIRE-deficient rats induces a severe autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy-like autoimmune disease[J]. J Immunol, 2018, 201(3): 874-887. PMID: 29959280. DOI: 10.4049/jimmunol.1701318.
36 Chascsa DM, Ferré EMN, Hadjiyannis Y, et al. APECED-associated hepatitis: clinical, biochemical, histological and treatment data from a large, predominantly American cohort[J]. Hepatology, 2021, 73(3): 1088-1104. PMID: 32557834. PMCID: PMC9169991. DOI: 10.1002/hep.31421.
37 Besnard M, Padonou F, Provin N, et al. AIRE deficiency, from preclinical models to human APECED disease[J]. Dis Model Mech, 2021, 14(2): dmm046359. PMID: 33729987. PMCID: PMC7875492. DOI: 10.1242/dmm.046359.
38 Besnard M, Sérazin C, Ossart J, et al. Anti-CD45RC antibody immunotherapy prevents and treats experimental autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome[J]. J Clin Invest, 2022, 132(7): e156507. PMID: 35167497. PMCID: PMC8970675. DOI: 10.1172/JCI156507.
39 de Souza FHC, Miossi R, de Moraes JCB, et al. Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies[J]. Adv Rheumatol, 2018, 58(1): 31. PMID: 30657080. DOI: 10.1186/s42358-018-0030-z.
40 Dunbar CE, High KA, Joung JK, et al. Gene therapy comes of age[J]. Science, 2018, 359(6372): eaan4672. PMID: 29326244. DOI: 10.1126/science.aan4672.
41 Zhang XE, Liu C, Dai J, et al. Enabling technology and core theory of synthetic biology[J]. Sci China Life Sci, 2023: 1-44. PMID: 36753021. PMCID: PMC9907219. DOI: 10.1007/s11427-022-2214-2. Epub ahead of print.
42 桂怡婷, 李强, 桂永浩. 罕见病的基因治疗应用与展望[J]. 临床儿科杂志, 2020, 38(10): 794-798. DOI: 10.3969/j.issn.1000-3606.2020.10.018.
43 Mendell JR, Al-Zaidy SA, Rodino-Klapac LR, et al. Current clinical applications of in vivo gene therapy with AAVs[J]. Mol Ther, 2021, 29(2): 464-488. PMID: 33309881. PMCID: PMC7854298. DOI: 10.1016/j.ymthe.2020.12.007.
44 Bulcha JT, Wang Y, Ma H, et al. Viral vector platforms within the gene therapy landscape[J]. Signal Transduct Target Ther, 2021, 6(1): 53. PMID: 33558455. PMCID: PMC7868676. DOI: 10.1038/s41392-021-00487-6.
45 Huang CH, Yang CM, Yang CH, et al. Leber's congenital amaurosis: current concepts of genotype-phenotype correlations[J]. Genes (Basel), 2021, 12(8): 1261. PMID: 34440435. PMCID: PMC8392113. DOI: 10.3390/genes12081261.
46 Padhy SK, Takkar B, Narayanan R, et al. Voretigene neparvovec and gene therapy for Leber's congenital amaurosis: review of evidence to date[J]. Appl Clin Genet, 2020, 13: 179-208. PMID: 33268999. PMCID: PMC7701157. DOI: 10.2147/TACG.S230720.
47 Gange WS, Sisk RA, Besirli CG, et al. Perifoveal chorioretinal atrophy after subretinal voretigene neparvovec-rzyl for RPE65-mediated Leber congenital amaurosis[J]. Ophthalmol Retina, 2022, 6(1): 58-64. PMID: 33838313. PMCID: PMC8497635. DOI: 10.1016/j.oret.2021.03.016.
48 Tjondrokoesoemo A, Schips TG, Sargent MA, et al. Cathepsin S contributes to the pathogenesis of muscular dystrophy in mice[J]. J Biol Chem, 2016, 291(19): 9920-9928. PMID: 26966179. PMCID: PMC4858995. DOI: 10.1074/jbc.M116.719054.
49 Asher DR, Thapa K, Dharia SD, et al. Clinical development on the frontier: gene therapy for Duchenne muscular dystrophy[J]. Expert Opin Biol Ther, 2020, 20(3): 263-274. PMID: 32031420. DOI: 10.1080/14712598.2020.1725469.
50 Abreu NJ, Waldrop MA. Overview of gene therapy in spinal muscular atrophy and Duchenne muscular dystrophy[J]. Pediatr Pulmonol, 2021, 56(4): 710-720. PMID: 32886442. DOI: 10.1002/ppul.25055.
51 Song Y, Morales L, Malik AS, et al. Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models[J]. Nat Med, 2019, 25(10): 1505-1511. PMID: 31591596. PMCID: PMC7274039. DOI: 10.1038/s41591-019-0594-0.
52 Malik MA, Masab M. Wiskott-Aldrich Syndrome[M]//StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing.
53 Magnani A, Semeraro M, Adam F, et al. Long-term safety and efficacy of lentiviral hematopoietic stem/progenitor cell gene therapy for Wiskott-Aldrich syndrome[J]. Nat Med, 2022, 28(1): 71-80. PMID: 35075289. PMCID: PMC8799465. DOI: 10.1038/s41591-021-01641-x.
54 Rai R, Romito M, Rivers E, et al. Targeted gene correction of human hematopoietic stem cells for the treatment of Wiskott-Aldrich syndrome[J]. Nat Commun, 2020, 11(1): 4034. PMID: 32788576. PMCID: PMC7423939. DOI: 10.1038/s41467-020-17626-2.
55 Ciftciler R, Goker H, Buyukas?k Y, et al. The experience of allogeneic hematopoietic stem cell transplantation in a patient with X-linked adrenoleukodystrophy[J]. Transfus Apher Sci, 2020, 59(1): 102583. PMID: 31350055. DOI: 10.1016/j.transci.2019.06.019.
56 Zhu J, Eichler F, Biffi A, et al. The changing face of adrenoleukodystrophy[J]. Endocr Rev, 2020, 41(4): 577-593. PMID: 32364223. PMCID: PMC7286618. DOI: 10.1210/endrev/bnaa013.
57 Klim JR, Vance C, Scotter EL. Antisense oligonucleotide therapies for amyotrophic lateral sclerosis: existing and emerging targets[J]. Int J Biochem Cell Biol, 2019, 110: 149-153. PMID: 30904737. DOI: 10.1016/j.biocel.2019.03.009.
58 Aoki Y, Wood MJA. Emerging oligonucleotide therapeutics for rare neuromuscular diseases[J]. J Neuromuscul Dis, 2021, 8(6): 869-884. PMID: 34092651. PMCID: PMC8673547. DOI: 10.3233/JND-200560.
59 Miller TM, Pestronk A, David W, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study[J]. Lancet Neurol, 2013, 12(5): 435-442. PMID: 23541756. PMCID: PMC3712285. DOI: 10.1016/S1474-4422(13)70061-9.
60 Alfano LN, Charleston JS, Connolly AM, et al. Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy[J]. Medicine (Baltimore), 2019, 98(26): e15858. PMID: 31261494. PMCID: PMC6617421. DOI: 10.1097/MD.0000000000015858.
61 Aartsma-Rus A, Arechavala-Gomeza V. Why dystrophin quantification is key in the eteplirsen saga[J]. Nat Rev Neurol, 2018, 14(8): 454-456. PMID: 29967362. DOI: 10.1038/s41582-018-0033-8.
62 Frank DE, Schnell FJ, Akana C, et al. Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy[J]. Neurology, 2020, 94(21): e2270-e2282. PMID: 32139505. PMCID: PMC7357297. DOI: 10.1212/WNL.0000000000009233.
63 McShane A, Mole SE. Sex bias and omission exists in Batten disease research: systematic review of the use of animal disease models[J]. Biochim Biophys Acta Mol Basis Dis, 2022, 1868(11): 166489. PMID: 35840041. DOI: 10.1016/j.bbadis.2022.166489.
64 Kim J, Hu C, Moufawad El Achkar C, et al. Patient-customized oligonucleotide therapy for a rare genetic disease[J]. N Engl J Med, 2019, 381(17): 1644-1652. PMID: 31597037. PMCID: PMC6961983. DOI: 10.1056/NEJMoa1813279.
65 Rubio T, Viana R, Moreno-Estellés M, et al. TNF and IL6/Jak2 signaling pathways are the main contributors of the glia-derived neuroinflammation present in Lafora disease, a fatal form of progressive myoclonus epilepsy[J]. Neurobiol Dis, 2023, 176: 105964. PMID: 36526090. DOI: 10.1016/j.nbd.2022.105964.
66 Mollá B, Heredia M, Sanz P. Modulators of neuroinflammation have a beneficial effect in a Lafora disease mouse model[J]. Mol Neurobiol, 2021, 58(6): 2508-2522. PMID: 33447969. PMCID: PMC8167455. DOI: 10.1007/s12035-021-02285-1.
67 Cuesta AM, Gallardo-Vara E, Casado-Vela J, et al. The role of propranolol as a repurposed drug in rare vascular diseases[J]. Int J Mol Sci, 2022, 23(8): 4217. PMID: 35457036. PMCID: PMC9025921. DOI: 10.3390/ijms23084217.
68 Dimiene I, Bieksiene K, Zaveckiene J, et al. Effective initial treatment of diffuse pulmonary lymphangiomatosis with sirolimus and propranolol: a case report[J]. Medicina (Kaunas), 2021, 57(12): 1308. PMID: 34946253; PMCID:PMC8706407. DOI: 10.3390/medicina57121308.
69 Davison AS, Norman B, Milan AM, et al. Assessment of the effect of once daily nitisinone therapy on 24-h urinary metadrenalines and 5-hydroxyindole acetic acid excretion in patients with alkaptonuria after 4 weeks of treatment[J]. JIMD Rep, 2018, 41: 1-10. PMID: 29147990. PMCID: PMC6122050. DOI: 10.1007/8904_2017_72.
70 Zatkova A, Ranganath L, Kadasi L. Alkaptonuria: current perspectives[J]. Appl Clin Genet, 2020, 13: 37-47. PMID: 32158253. PMCID: PMC6986890. DOI: 10.2147/TACG.S186773.
71 Vilboux T, Kayser M, Introne W, et al. Mutation spectrum of homogentisic acid oxidase (HGD) in alkaptonuria[J]. Hum Mutat, 2009, 30(12): 1611-1619. PMID: 19862842. PMCID: PMC2830005. DOI: 10.1002/humu.21120.